| [1] |
Jones PA, Ohtani H, Chakravarthy A, et al. Epigenetic therapy in immune-oncology [J]. Nat Rev Cancer, 2019, 19(3): 151-161.
|
| [2] |
Emmett MJ, Lazar MA. Integrative regulation of physiology by histone deacetylase 3 [J]. Nat Rev Mol Cell Biol, 2019, 20(2): 102-115.
|
| [3] |
Liang T, Fang H. Structure, functions and selective inhibitors of HDAC6 [J]. Curr Top Med Chem, 2018, 18(28): 2429-2447.
|
| [4] |
Batchu SN, Brijmohan AS, Advani A. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease [J]. Clin Sci, 2016, 130(12): 987-1003.
|
| [5] |
Kosciuk T, Wang M, Hong JY, et al. Updates on the epigenetic roles of sirtuins [J]. Curr Opin Chem Biol, 2019, 51: 18-29.
|
| [6] |
Sun L, Marin de Evsikova C, Bian K, et al. Programming and regulation of metabolic homeostasis by HDAC11 [J]. EBioMedicine, 2018, 33: 157-168.
|
| [7] |
Zupkovitz G, Lagger S, Martin D, et al. Histone deacetylase 1 expression is inversely correlated with age in the short-lived fish Nothobranchius furzeri [J]. Histochem Cell Biol, 2018, 150(3): 255-269.
|
| [8] |
Bacon T, Seiler C, Wolny M, et al. Histone deacetylase 3 indirectly modulates tubulin acetylation [J]. Biochem J, 2015, 472(3): 367-377.
|
| [9] |
Zhang CL, McKinsey TA, Chang S, et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy [J]. Cell, 2002, 110(4): 479-488.
|
| [10] |
Chen S, El-Dahr SS. Histone deacetylases in kidney development: implications for disease and therapy [J]. Pediatr Nephrol, 2013, 28(5): 689-698.
|
| [11] |
Qin HT, Li HQ, Liu F. Selective histone deacetylase small molecule inhibitors: recent progress and perspectives [J]. Expert Opin Ther Pat, 2017, 27(5): 621-636.
|
| [12] |
Shi Y, Xu L, Tang J, et al. Inhibition of HDAC6 protects against rhabdomyolysis-induced acute kidney injury [J]. Am J Physiol Renal Physiol, 2017, 312(3): F502-F515.
|
| [13] |
Tang J, Shi Y, Liu N, et al. Blockade of histone deacetylase 6 protects against cisplatin-induced acute kidney injury [J]. Clin Sci, 2018, 132(3): 339-359.
|
| [14] |
Feng Y, Huang R, Guo F, et al. Selective histone deacetylase 6 inhibitor 23BB alleviated rhabdomyolysis-induced acute kidney injury by regulating endoplasmic reticulum stress and apoptosis [J]. Front Pharmacol, 2018, 9: 274.
|
| [15] |
Marumo T, Hishikawa K, Yoshikawa M, et al. Epigenetic regulation of BMP7 in the regenerative response to ischemia [J]. J Am Soc Nephrol, 2008, 19(7): 1311-1320.
|
| [16] |
Zeisberg M, Hanai J, Sugimoto H, et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury [J]. Nat Med, 2003, 9(7): 964-968.
|
| [17] |
Imai N, Hishikawa K, Marumo T, et al. Inhibition of histone deacetylase activates side population cells in kidney and partially reverses chronic renal injury [J]. Stem Cells, 2007, 25(10): 2469-2475.
|
| [18] |
de Boer IH. A new chapter for diabetic kidney disease [J]. N Engl J Med, 2017, 377(9): 885-887.
|
| [19] |
Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney [J]. Nat Rev Nephrol, 2017, 13(10): 629-646.
|
| [20] |
Advani A, Huang Q, Thai K, et al. Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanism [J]. Am J Pathol, 2011, 178(5): 2205-2214.
|
| [21] |
Gilbert RE, Huang Q, Thai K, et al. Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor [J]. Kidney Int, 2011, 79(12): 1312-1321.
|
| [22] |
Noh H, Oh EY, Seo JY, et al. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury [J]. Am J Physiol Renal Physiol, 2009, 297(3): F729-F739.
|
| [23] |
Tan AY, Zhang T, Michaeel A, et al. Somatic mutations in renal cyst epithelium in autosomal dominant polycystic kidney disease [J]. J Am Soc Nephrol, 2018, 29(8): 2139-2156.
|
| [24] |
Cao Y, Semanchik N, Lee SH, et al. Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models [J]. Proc Natl Acad Sci USA, 2009, 106(51): 21819-21824.
|
| [25] |
Zhou X, Fan LX, Sweeney WE, et al. Sirtuin 1 inhibition delays cyst formation in autosomal-dominant polycystic kidney disease [J]. J Clin Invest, 2013, 123(7): 3084-3098.
|
| [26] |
Li Y, Zhang X, Polakiewicz RD, et al. HDAC6 is required for epidermal growth factor-induced beta-catenin nuclear localization [J]. J Biol Chem, 2008, 283(19): 12686-12690.
|
| [27] |
Pang M, Kothapally J, Mao H, et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy [J]. Am J Physiol Renal Physiol, 2009, 297(4): F996-F1005.
|
| [28] |
Choi SY, Piao ZH, Jin L, et al. Piceatannol attenuates renal fibrosis induced by unilateral ureteral obstruction via downregulation of histone deacetylase 4/5 or p38-MAPK signaling [J]. PLoS One, 2016, 11(11): e0167340.
|
| [29] |
Marumo T, Hishikawa K, Yoshikawa M, et al. Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury [J]. Am J Physiol Renal Physiol, 2010, 298(1): F133-F141.
|
| [30] |
Van Beneden K, Geers C, Pauwels M, et al. Comparison of trichostatin A and valproic acid treatment regimens in a mouse model of kidney fibrosis [J]. Toxicol Applied Pharmacol, 2013, 271(2): 276-284.
|